Angel Guerrero-Zotano, Medical Oncologist at Instituto Valenciano de Oncologia, shared a post on X:
“Can we assess tumor proliferation in blood? In Ph III PEARL, GEICAM, circulating TKa by FDA/CE-cleared assay predicted PFS/OS in HR+/HER2− MBC, with early dynamics capturing tx-specific biology.
Growing evidence; ready for clinical validation.”
Title: Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial
Authors: Ángel Guerrero-Zotano, Miguel Gil-Gil, Amy Williams, Manuel Ruiz-Borrego, Hanna Ritzén, Eva María Ciruelos, Montserrat Muñoz, Begoña Bermejo, Mireia Margelí, Antonio Antón, Zsuzsanna Kahan, Tibor Csösz, Laura Murillo, Serafín Morales Murillo, Istvan Lang, Cristina Reboredo Rendo, Emilio Alba, Pablo Álvarez, Juan de la Haba-Rodríguez, Isabel Álvarez, Andrés García, Jesús Herranz, Rosalía Caballero, Helle Fisker, Marta Portela, Federico Rojo, Miguel Martín
Read the Full Article.
